The DEA Rescheduling Hearing Is Over. A New Commentary Argues States Should Lead the Next Phase of Cannabis Research
The DEA rescheduling hearing has concluded, but the clinical benefits depend on state cannabis research policy. States with mature medical programs must build infrastructure to convert lowered federal barriers into usable clinical evidence. This…
The DEA Rescheduling Hearing Is Over. States Should Lead Cannabis Research
State-led cannabis research infrastructure: The DEA rescheduling hearing concluded in July 2026, marking a procedural milestone. Experts argue that the clinical benefits of rescheduling depend on states building dedicated cannabis research…
Terrapin Urges State Action After DOJ Medical Marijuana Rescheduling
The DOJ medical marijuana rescheduling impact signals a major federal policy shift from Schedule I to Schedule III. This change could improve research access and reduce barriers for patients. States are now urged to adapt their medical cannabis programs…
Continuing Efforts to See Cannabis Declassified | Congressman Steve Cohen
Cannabis descheduling clinical implications are significant for research and medical practice. Federal policy reform could remove barriers to clinical trials and improve patient access. Understanding these changes helps clinicians prepare for future…
US Marijuana Reclassification: What It Means for Florida
Federal cannabis reclassification policy changes could reshape research and legal frameworks. While not legalizing cannabis federally, these changes reduce regulatory barriers. Florida's medical cannabis program remains governed by state law despite…
Trump Complains DOJ Is ‘Slow-Walking’ Marijuana Rescheduling, Four Months After He Issued Order
Marijuana rescheduling delays continue to affect clinical practice and research opportunities. The federal cannabis policy update remains uncertain, impacting prescribing protocols. Clinicians must monitor these regulatory changes closely to adapt…